MedTrace Logo

Differential Target Multiplexed Spinal Cord Stimulation (DTM-SCS®) Real World Outcomes

NCT04725838 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 255

Last updated 2024-08-21

No results posted yet for this study

Summary

The UPGRADE registry will capture long-term, real-world outcomes to understand the effect of Differential Target Multiplexed (DTM®) programming in the Spinal Cord Stimulation (SCS) implanted population on the management of chronic pain, primarily on its use for trunk and/or limb pain. The clinical study is sponsored by Celéri Health and is funded through a financial grant from Medtronic's External Research Program. The registry study will be conducted across approximately 25 centers in the United States with up to 600 participants enrolled.

Conditions

Interventions

DEVICE

Medtronic Intellis™ and Vanta™

Differential Target Multiplexed (DTM®) programming using Medtronic's Intellis™ or Vanta™ Spinal Cord Stimulation systems

Sponsors & Collaborators

  • Medtronic

    collaborator INDUSTRY

  • Celéri Health, Inc.

    lead INDUSTRY

Principal Investigators

  • Michael Fishman, MD · Chief Medical Officer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-29
Primary Completion
2023-07-01
Completion
2023-07-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04725838 on ClinicalTrials.gov